Efficacy and Safety of VB421 in Subjects With Thyroid Eye Disease (TED)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Phase 1b, multicenter, double-masked, placebo-controlled, randomized, MAD clinical study is
designed to evaluate VB421 versus placebo in subjects with TED.